A coagulation panel evaluates how well blood forms a fibrin clot and helps identify bleeding risk, thrombosis risk, liver dysfunction, vitamin K deficiency, and anticoagulant effects. This cheat sheet focuses on PT, aPTT, and INR, the core screening tests used in clinical medicine. College students need these tests because they connect biochemistry, hematology, pharmacology, and patient safety.
Understanding the pathway each test measures makes abnormal results easier to interpret.
Key Facts
- PT primarily evaluates the extrinsic and common pathways, especially factors VII, X, V, II, and fibrinogen.
- aPTT primarily evaluates the intrinsic and common pathways, including factors XII, XI, IX, VIII, X, V, II, and fibrinogen.
- INR standardizes PT across laboratories and is calculated as INR = (patient PT / mean normal PT)^ISI.
- A prolonged PT with a normal aPTT often suggests factor VII deficiency, early vitamin K deficiency, early warfarin effect, or mild liver disease.
- A prolonged aPTT with a normal PT can suggest heparin effect, hemophilia A or B, factor XI deficiency, lupus anticoagulant, or contact factor deficiency.
- Both prolonged PT and prolonged aPTT can occur with severe liver disease, disseminated intravascular coagulation, severe vitamin K deficiency, massive transfusion, or common pathway factor deficiency.
- A mixing study compares patient plasma mixed 1:1 with normal plasma; correction suggests factor deficiency, while failure to correct suggests an inhibitor.
- Warfarin mainly prolongs PT and INR by reducing vitamin K dependent factors II, VII, IX, and X, while unfractionated heparin usually prolongs aPTT.
Vocabulary
- Prothrombin Time
- Prothrombin time is the number of seconds required for plasma to clot after tissue factor and calcium are added, mainly testing the extrinsic and common pathways.
- Activated Partial Thromboplastin Time
- Activated partial thromboplastin time is the number of seconds required for plasma to clot after intrinsic pathway activation, phospholipid, and calcium are added.
- International Normalized Ratio
- International normalized ratio is a standardized form of PT used especially to monitor warfarin therapy across different laboratories.
- Intrinsic Pathway
- The intrinsic pathway is the coagulation pathway measured by aPTT and includes factors XII, XI, IX, and VIII before joining the common pathway.
- Extrinsic Pathway
- The extrinsic pathway is the coagulation pathway measured by PT and begins with tissue factor and factor VII activation.
- Mixing Study
- A mixing study is a laboratory test that mixes patient plasma with normal plasma to help distinguish factor deficiency from an inhibitor.
Common Mistakes to Avoid
- Assuming PT and INR are separate pathway tests is wrong because INR is a standardized calculation based on PT, not an independent clotting assay.
- Interpreting a prolonged aPTT as bleeding risk in every case is wrong because lupus anticoagulant can prolong aPTT while increasing thrombosis risk rather than causing bleeding.
- Ignoring medication history is wrong because warfarin, unfractionated heparin, direct thrombin inhibitors, and factor Xa inhibitors can all alter coagulation tests.
- Using a normal PT and aPTT to rule out all bleeding disorders is wrong because platelet disorders, von Willebrand disease, and mild factor deficiencies may have normal screening tests.
- Assuming mixing study correction always proves one specific factor deficiency is wrong because correction only suggests deficient clotting activity and must be followed by targeted factor assays.
Practice Questions
- 1 A patient has PT = 24 seconds, mean normal PT = 12 seconds, and ISI = 1.0. Calculate the INR.
- 2 A patient has PT = 13 seconds and aPTT = 72 seconds. Which pathway is most likely affected, and name two possible causes.
- 3 A 1:1 mixing study changes aPTT from 80 seconds to 34 seconds, with a normal control range of 25 to 35 seconds. Does this pattern suggest a factor deficiency or an inhibitor?
- 4 Explain why severe liver disease can prolong both PT and aPTT, while early warfarin therapy often prolongs PT before aPTT.
Understanding Coagulation Panel PT, aPTT, INR
Clotting is not a single event. It is a chain of protein activations that produces thrombin, an enzyme that changes soluble fibrinogen into fibrin strands. Fibrin forms a mesh that stabilizes the initial platelet plug at an injury site.
PT and aPTT are performed on platelet poor plasma, so they test clotting proteins rather than platelet number or platelet function. A person can therefore have easy bruising or mucosal bleeding from low platelets while these tests remain normal.
Conversely, an abnormal clotting time does not always mean active bleeding. The result must be considered with the patient’s symptoms, medication history, and other blood tests.
The laboratory starts each test by adding carefully chosen reagents to citrated plasma. Citrate temporarily binds calcium and prevents the sample from clotting in the collection tube. The analyzer then returns calcium under controlled conditions and measures the time until a clot forms.
PT reagents contain tissue factor, which starts the pathway used after damaged tissue exposes this protein. Different laboratories use different tissue factor reagents, and these reagents do not respond equally to reduced clotting factors.
INR adjusts PT results so that warfarin monitoring can be compared more reliably between laboratories. This standardization is most useful for warfarin and should not be treated as a universal measure of bleeding risk.
A prolonged result is a clue, not a final diagnosis. A mixing study helps separate two broad causes. The laboratory combines patient plasma with normal plasma, which supplies missing clotting factors.
If the clotting time returns toward normal, a factor deficiency becomes more likely. If it stays prolonged, an interfering substance or antibody becomes more likely. Some inhibitors need time at body temperature before their effect appears, so laboratories may measure the mixture immediately and after incubation.
Lupus anticoagulant is an important example. It can prolong aPTT in a tube while being linked to clot formation in the body rather than bleeding. This apparent contradiction is a key point for students to remember.
Sample quality can change results before testing even begins. The blue top citrate tube must be filled to its marked level because the blood to citrate ratio matters. An underfilled tube has too much citrate and may give falsely prolonged times.
A very high red cell concentration can create a similar problem because there is less plasma in the collected blood. Delayed processing, contamination with heparin from an intravenous line, and recent transfusion can complicate interpretation. Direct oral anticoagulants may affect PT or aPTT unpredictably, so normal screening tests do not prove that these drugs are absent.
In clinical practice, doctors often compare results with platelet count, fibrinogen, liver tests, kidney function, and the timing of the last anticoagulant dose. Patterns are useful, but careful context prevents unsafe conclusions.